Literature DB >> 20200337

Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: a genetics of diabetes audit and research Tayside study.

Lindsay R Burch1, Louise A Donnelly, Alex S F Doney, Jeffrey Brady, Anna M Tommasi, Adrian L Whitley, Catharine Goddard, Andrew D Morris, Michael K Hansen, Colin N A Palmer.   

Abstract

CONTEXT: Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity.
OBJECTIVE: The objective of the study was to determine whether rs2016520 or other single-nucleotide polymorphism in the PPARD locus influenced the risk of developing various characteristics of metabolic disease.
DESIGN: Haplotype tagging analysis across PPARD was performed in 11,074 individuals from the Welcome Trust U.K. Type 2 Diabetes Case Control Collection.
RESULTS: In subjects with and without type 2 diabetes, rs2016520 was associated with body mass index, high-density lipoprotein cholesterol, leptin, and TNFalpha and was dependent on gender.
CONCLUSION: The current results suggest differential effects of PPARdelta in males and females.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20200337     DOI: 10.1210/jc.2009-1201

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  PPARβ/δ modulates ethanol-induced hepatic effects by decreasing pyridoxal kinase activity.

Authors:  Maryam Goudarzi; Takayuki Koga; Combiz Khozoie; Tytus D Mak; Boo-Hyon Kang; Albert J Fornace; Jeffrey M Peters
Journal:  Toxicology       Date:  2013-07-10       Impact factor: 4.221

Review 2.  Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.

Authors:  Salman Azhar
Journal:  Future Cardiol       Date:  2010-09

3.  Hematopoietic knockdown of PPARδ reduces atherosclerosis in LDLR-/- mice.

Authors:  G Li; C Chen; S D Laing; C Ballard; K C Biju; R L Reddick; R A Clark; S Li
Journal:  Gene Ther       Date:  2015-08-23       Impact factor: 5.250

4.  Effect of genetic polymorphism +294T/C in peroxisome proliferator-activated receptor delta on the risk of ischemic stroke in a Tunisian population.

Authors:  Khouloud Chehaibi; Mohamed Yahia Hrira; Mustapha Rouis; Mohamed Najah; Imen Jguirim-Souissi; Samir Nouira; Mohamed Naceur Slimane
Journal:  J Mol Neurosci       Date:  2013-03-20       Impact factor: 3.444

5.  Peroxisome proliferator-activated receptor delta +294T > C polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations.

Authors:  Lin Miao; Rui-Xing Yin; Dong-Feng Wu; Xiao-Li Cao; Qing Li; Xi-Jiang Hu; Ting-Ting Yan; Lynn Htet Htet Aung; De-Zhai Yang; Wei-Xiong Lin
Journal:  Lipids Health Dis       Date:  2010-12-21       Impact factor: 3.876

6.  The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.

Authors:  M C Thomas; K A Jandeleit-Dahm; C Tikellis
Journal:  PPAR Res       Date:  2012-02-12       Impact factor: 4.964

7.  The peroxisome proliferator-activated receptor delta +294T > C polymorphism and alcohol consumption on serum lipid levels.

Authors:  Xian-Liang Wei; Rui-Xing Yin; Lin Miao; Dong-Feng Wu
Journal:  Lipids Health Dis       Date:  2011-12-23       Impact factor: 3.876

8.  PPARD +294C overrepresentation in general and long-lived population in China Bama longevity area and unique relationships between PPARD +294T/C polymorphism and serum lipid profiles.

Authors:  Chen-Yuan Luo; Cheng-Wu Liu; Lin Ge; Guo-Fang Pang; Ming Yang; Cai-You Hu; Ze-Ping Lv; Ning-Yuan Chen; Hai-Yan Li; Hua-Yu Wu; Yi-Yuan Wang; Rui-Xing Yin; Shang-Ling Pan; Jun-Hua Peng
Journal:  Lipids Health Dis       Date:  2015-03-07       Impact factor: 3.876

9.  Several genetic polymorphisms interact with overweight/obesity to influence serum lipid levels.

Authors:  Rui-Xing Yin; Dong-Feng Wu; Lin Miao; Lynn Htet Htet Aung; Xiao-Li Cao; Ting-Ting Yan; Xing-Jiang Long; Wan-Ying Liu; Lin Zhang; Meng Li
Journal:  Cardiovasc Diabetol       Date:  2012-10-08       Impact factor: 9.951

10.  Mixed modeling of meta-analysis P-values (MixMAP) suggests multiple novel gene loci for low density lipoprotein cholesterol.

Authors:  Andrea S Foulkes; Gregory J Matthews; Ujjwal Das; Jane F Ferguson; Rongheng Lin; Muredach P Reilly
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.